The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial
Abstract
Purpose To compare the effects of insulin sensitizers metformin (MET) and myo-inositol (MI) on adiponectin levels and metabolic characteristics in women with polycystic ovary syndrome (PCOS) with respect to their body mass index (BMI).Methods In this open label, parallel randomized clinical trial, 66 women with PCOS (33 normal-weight and 33 overweight/obese) were randomized to either MI (4 g/day) or MET (1500 mg/day) for a period of 6 months. Serum concentration of adiponectin, hormonal and metabolic laboratory outcomes and clinical assessment of BMI, body composition and Ferriman-Gallwey score (FG score) were evaluated before and after treatment.Results After the 6-month intervention, comparison between MET and MI in time to treatment analysis showed no significant differences between the two treatments for all analyzed parameters. Only borderline significantly lower AUC glucose was found in the MET group in comparison to the MI group (p = 0.071). The main effect of treatment was shown for glucose concentration at 120 min OGTT (p = 0.032) and testosterone (p = 0.002). The main effect of time was shown for body mass (p = 0.004), waist circumference (p < 0.001), BMI (p = 0.003), body fat mass (p = 0.001), adiponectin (p = 0.020), fasting glucose (p = 0.001), testosterone (p = 0.015), SHBG (p = 0.013), 17OH progesterone (p = 0.008), LH (p = 0.004) and estradiol (p = 0.014).Conclusion Our study showed similar effects of MET and MI on BMI, body composition, hormonal profile, metabolism of glucose and insulin, and adiponectin level. The two insulin sensitizers, MET and MI, were useful in reducing BMI and improving body composition without significant differences between the two treatments in PCOS women.Trial registration ISRCTN13199265. Trial registration date: 14.04.2021. (ISRCTN Registry), retrospectively registered.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In meta-analysis for androgenicity, metformin was superior to MI for FG score in 2 trials (MD 2.42, Fig. 5A) (26, 53), while MI was superior to metformin for SHBG (MD 3.85, Fig. 5C, 2 studies) (26, 53), with no differences in total testosterone in 4 trials (Fig. 5B) (26, 41, 42, 51, 53).”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [53]
In the citing paper
“In meta-analysis for androgenicity, metformin was superior to MI for FG score in 2 trials (MD 2.42, Fig. 5A) (26, 53), while MI was superior to metformin for SHBG (MD 3.85, Fig. 5C, 2 studies) (26, 53), with no differences in total testosterone in 4 trials (Fig. 5B) (26, 41, 42, 51, 53).”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [53]
In the citing paper
“There were no differences between groups for metabolic, lipid, and most anthropometric outcomes including fasting glucose (Fig. 5D, 4 studies) (26, 41, 42, 51, 53), fasting insulin (Fig. 5E, 5 studies) (26, 30, 41, 42, 51, 53), HOMA-IR (Fig. 5F, 5 studies) (26, 33, 41, 42, 51, 53), total cholesterol, HDL, and LDL cholesterol (Fig. 5G–5I, 2 studies) (41, 42, 51), weight (Fig. 5J, 3 studies) (30, 41”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [53]
In the citing paper
“In meta-analysis for androgenicity, metformin was superior to MI for FG score in 2 trials (MD 2.42, Fig. 5A) (26, 53), while MI was superior to metformin for SHBG (MD 3.85, Fig. 5C, 2 studies) (26, 53), with no differences in total testosterone in 4 trials (Fig. 5B) (26, 41, 42, 51, 53).”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [53]
In the citing paper
“There were no differences between groups for metabolic, lipid, and most anthropometric outcomes including fasting glucose (Fig. 5D, 4 studies) (26, 41, 42, 51, 53), fasting insulin (Fig. 5E, 5 studies) (26, 30, 41, 42, 51, 53), HOMA-IR (Fig. 5F, 5 studies) (26, 33, 41, 42, 51, 53), total cholesterol, HDL, and LDL cholesterol (Fig. 5G–5I, 2 studies) (41, 42, 51), weight (Fig. 5J, 3 studies) (30, 41”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [53]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
Paradoxical Decrease of an Adipose-Specific Protein, Adiponectin, in Obesity
Arita, Y., Kihara, S., Ouchi, N., Takahashi, M., Maeda, K., Miyagawa, J.-I., Hotta, K., Shimomura, I., Nakamura, T., Miyaoka, K., et al. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0255 · Cited by 4,856
The Diagnosis of Polycystic Ovary Syndrome during Adolescence
Witchel, S. F., Oberfield, S., Rosenfield, R. L., Codner, E., Bonny, A., Ibáñez, L., Pena, A., Horikawa, R., Gomez-Lobo, V., Joel, D., et al. (2015) · Hormone Research in Paediatrics · doi:10.1159/000375530 · Cited by 3,113
Tang, T., Lord, J. M., Norman, R. J., Yasmin, E., & Balen, A. H. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003053.pub5 · Cited by 698
The polycystic ovary syndrome: a position statement from the European Society of Endocrinology
Conway, G., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Franks, S., Gambineri, A., Kelestimur, F., Macut, D., Micic, D., Pasquali, R., et al. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0253 · Cited by 676
Self-citationMoghetti, P., Castello, R., Negri, C., Tosi, F., Perrone, F., Caputo, M., Zanolin, E., & Muggeo, M. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.1.6293 · Cited by 660
Pasquali, R., Gambineri, A., Biscotti, D., Vicennati, V., Gagliardi, L., Colitta, D., Fiorini, S., Cognigni, G. E., Filicori, M., & Morselli-Labate, A. M. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.8.6738 · Cited by 635
Removal of Visceral Fat Prevents Insulin Resistance and Glucose Intolerance of Aging
Gabriely, I., Ma, X. H., Yang, X. M., Atzmon, G., Rajala, M. W., Berg, A. H., Scherer, P., Rossetti, L., & Barzilai, N. (2002) · Diabetes · doi:10.2337/diabetes.51.10.2951 · Cited by 563
Escobar-Morreale, H. F., Carmina, E., Dewailly, D., Gambineri, A., Kelestimur, F., Moghetti, P., Pugeat, M., Qiao, J., Wijeyaratne, C. N., Witchel, S. F., et al. (2012) · Human Reproduction Update · doi:10.1093/humupd/dmr042 · Cited by 494
Cited by
Greff, D., Juhász, A. E., Váncsa, S., Váradi, A., Sipos, Z., Szinte, J., Park, S., Hegyi, P., Nyirády, P., Ács, N., et al. (2023) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-023-01055-z · Cited by 143
“In the case of DHEAS and androstenedione, no significant difference was found.”
BackgroundInfluentialFitz, V., Graca, S., Mahalingaiah, S., Liu, J., Lai, L., Butt, A., Armour, M., Rao, V., Naidoo, D., Maunder, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad762 · Cited by 70
“5E, 5 studies) (26, 30, 41, 42, 51, 53), HOMA-IR (Fig.”
BackgroundInfluentialAdamczak, R., Ukleja-Sokołowska, N., Lis, K., & Dubiel, M. (2021) · Medicina · doi:10.3390/medicina57111251 · Cited by 65
Mladenović, D. R., Vesković, M. N., Šutulović, N., Hrnčić, D., Stanojlović, O. P., Radić, L., Macut, J. B., & Μacut, D. (2024) · Endocrine · doi:10.1007/s12020-024-03702-w · Cited by 37
Fiore, G., Pascuzzi, M. C., Profio, E. D., Corsello, A., Agostinelli, M., Mendola, A. L., Milanta, C., Campoy, C., Calcaterra, V., Zuccotti, G., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106599 · Cited by 32
Metadata
- Authors
- Soldat-Stanković, V., Popović-Pejičić, S., Stanković, S., Prtina, A., Malešević, G., Bjekić-Macut, J., Livadas, S., Ognjanović, S., Mastorakos, G., Micić, D., & Macut, D.
- Affiliations
- University of Banja Luka (BA)
- University of Belgrade (RS)
- Metropolitan Hospital (GR)
- National and Kapodistrian University of Athens (GR)
- Serbian Academy of Sciences and Arts (RS)
- Venue
- Journal of Endocrinological Investigation
- Published
- 2021-10-19
- Volume
- 45
- Issue
- 3
- Pages
- 583-595
- ISSN
- 0391-4097 (ISSN-L)
- 1720-8386
- OpenAlex
- W3205241365
- Cited by
- 37
- References
- 57
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 15 · 2023: 9 · 2022: 6 · 2021: 1
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Journal of Endocrinological Investigation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- polycystic ovary syndrome, metformin, myo-inositol, insulin sensitizers, adiponectin, body mass index, body composition, testosterone, insulin resistance, glucose metabolism, overweight and obesity, Ferriman-Gallwey score, sex hormone-binding globulin, luteinizing hormone, estradiol, 17-hydroxyprogesterone
- MeSH terms
- Adult, Blood Glucose, Body Composition, Female, Humans, Hypoglycemic Agents, Inositol, Insulin, Insulin Resistance, Metformin, Obesity, Polycystic Ovary Syndrome, Gonadal Steroid Hormones, Vitamin B Complex, Body Mass Index, Treatment Outcome, Adiponectin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial. https://app.cochat.ai/papers/10.1007/s40618-021-01691-5
- The paper
- Soldat-Stanković, V., Popović-Pejičić, S., Stanković, S., Prtina, A., Malešević, G., Bjekić-Macut, J., Livadas, S., Ognjanović, S., Mastorakos, G., Micić, D., & Macut, D. (2022). The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial. Journal of Endocrinological Investigation. https://doi.org/10.1007/s40618-021-01691-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.